Anna Alyasova - Researcher Profile | RDL Research Database

Publications

3 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 6,365

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-2621-0359

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.